4.5 Article

Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive

Journal

BREAST CANCER RESEARCH AND TREATMENT
Volume 113, Issue 1, Pages 181-187

Publisher

SPRINGER
DOI: 10.1007/s10549-008-9914-7

Keywords

HER-2; Steroid receptors; Lymph node; Breast cancer

Categories

Ask authors/readers for more resources

Aims To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status. Methods 2227 recently operated cases in one centre were retrieved from the Multidisciplinary Breast Centre database and stratified according to their combined immunohistochemical (IHC) expression of ER/PR/HER-2 status. An equivocal HER-2 status was further analysed by Fluorescence in situ Hybridisation (FISH). The following 6 groups were considered: ER-PR-HER-2(-) (NNN; triple negative), ER-PR-HER-2(+) (NNP), ER+PR-HER-2(-) (PNN), ER+PR-HER-2(+) (PNP), ER+PR+HER-2(-) (PPN), ER+PR+HER-2(+) (PPP; triple positive). For ALN, the following variables were tested in uni- and multivariate models: age at diagnosis (years), tumour size (mm), tumour grade, ER, PR, HER-2 and the combined steroid receptor and HER-2 status. Likelihood ratio chi(2)-tests were used for univariate analysis and logistic regression for multivariate analysis. Results Triple positive tumours had a higher likelihood of being ALN positive than others (56.2% versus 35.7%; P < 0.0001). Univariate logistic regression also withheld age, size, grade and HER-2 as predictors of ALN involvement. Final multivariate logistic regression revealed age, size, grade and PPP versus non-PPP to be independent predictors of ALN involvement; the odds ratio (OR) and 95% CI for PPP versus non-PPP tumours was 2.169 (1.490-3.156). Conclusion Our data provide insight into the natural history of triple positive breast carcinomas. Such tumours are more likely ALN positive than those with another steroid receptor and HER-2 status. How these findings correlate with breast cancer prognosis remains to be investigated.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Emiel A. De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen K. Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore G. Denys

Summary: The PRIMMO study conducted a phase II trial on patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer. The study found that pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail had modest but durable antitumor activity, with acceptable but not negligible toxicity.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Acoustics

Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

C. Landolfo, T. Bourne, W. Froyman, B. Van Calster, J. Ceusters, A. C. Testa, L. Wynants, P. Sladkevicius, C. Van Holsbeke, E. Domali, R. Fruscio, E. Epstein, D. Franchi, M. J. Kudla, V. Chiappa, J. L. Alcazar, F. P. G. Leone, F. Buonomo, M. E. Coccia, S. Guerriero, N. Deo, L. Jokubkiene, L. Savelli, D. Fischerova, A. Czekierdowski, J. Kaijser, A. Coosemans, G. Scambia, I. Vergote, D. Timmerman, L. Valentin

Summary: This study validated the use of modified benign simple descriptors (BDs) to exclude malignancy in most women with adnexal masses, and proposed a two-step strategy using the ADNEX model to estimate the risk of malignancy. The modified BDs were applicable to 37% of tumors, 99.3% of which were benign. The two-step strategy showed an AUC of 0.94.

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2023)

Article Obstetrics & Gynecology

1 Real-world assessment of the patient- centredness of endometriosis care: European countries benchmarked by patients

E. A. F. Dancet, L. Ameye, W. Sermeus, M. Welkenhuysen, K. T. Zondervan, C. De Cicco, V Mijatovic, A. Schreurs, D. Timmerman, T. M. D'Hooghe

Summary: European patients seek more patient-centred healthcare by crossing borders. This study validated the ENDOCARE questionnaire in nine different languages and demonstrated its benchmark potential. Significant between-country variance in case-mix-adjusted overall and dimensional patient-centredness scores explained 3-9% of the total variance in patient-centredness across 10 European countries. Compared to the least patient-centred country, endometriosis care in Denmark, Italy, and Belgium was more patient-centred.

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2023)

Article Health Care Sciences & Services

Minimum sample size for developing a multivariable prediction model using multinomial logistic regression

Alexander Pate, Richard D. Riley, Gary S. Collins, Maarten van Smeden, Ben Van Calster, Joie Ensor, Glen P. Martin

Summary: Multinomial logistic regression models are used to predict the risk of a categorical outcome with more than two categories. Researchers need to ensure that the number of participants is appropriate relative to the number of events and predictor variables for each category. This study proposes three criteria to determine the minimum required sample size, aiming to minimize overfitting, difference between observed and adjusted R-2 Nagelkerke, and ensure accurate estimation of overall risk. The criteria were evaluated through simulation study and applied to a worked example, with code provided for implementation in R and Stata.

STATISTICAL METHODS IN MEDICAL RESEARCH (2023)

Letter Multidisciplinary Sciences

University vice-chancellor responds

Ben Van Calster

NATURE (2023)

Letter Acoustics

Prospective geographical and temporal validation of three published mathematical models to calculate risk of endometrial malignancy in patients with postmenopausal bleeding

R. Heremans, T. van den Bosch, P. Sladkevicius, M. A. Pascual, J. L. Alcazar, D. Timmerman, L. Valentin

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2023)

Article Health Care Sciences & Services

Perspectives on validation of clinical predictive algorithms

Anne A. H. de Hond, Vaibhavi B. B. Shah, Ilse M. J. Kant, Ben Van Calster, Ewout W. Steyerberg, Tina Hernandez-Boussard

Summary: The generalizability of predictive algorithms is crucial for their application in clinical practice. This article provides an overview of three types of generalizability, namely temporal, geographical, and domain generalizability, based on existing literature. These types of generalizability are associated with their respective goals, methodology, and stakeholders.

NPJ DIGITAL MEDICINE (2023)

Letter Medical Laboratory Technology

Ultrasensitive Microhaplotype-Based Detection of Minor Alleles in Cervical Samples of Pregnant Women Identifies Sperm Rather Than Fetal DNA

Margot van Riel, Yan Zhao, Tatjana Jatsenko, Lore Lannoo, Dirk Timmerman, Joris R. Vermeesch

CLINICAL CHEMISTRY (2023)

Article Oncology

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix, Ignace Vergote, Pieter Busschaert, Adriaan Vanderstichele, Tom Venken, Bram Boeckx, Philipp Harter, Hilde Brems, Els Van Nieuwenhuysen, Sandro Pignata, Thais Baert, Antonio Gonzalez-Martin, Sileny Han, Christian Marth, Patrick Neven, Nicoletta Colombo, Patrick Berteloot, Johanna Maeenpaeae, Siel Olbrecht, Tina Laga, Erwin Sablon, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Diether Lambrechts, Toon Van Gorp

Summary: The Leuven HRD test and Myriad HRD test have similar predictive value for PFS and OS in HRD+ patients, and there is a robust correlation between the two tests.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

I. Vergote, E. Van Nieuwenhuysen, A. Casado, A. Laenen, D. Lorusso, E. I. Braicu, E. Guerra-Alia, P. Zola, P. Wimberger, P. R. Debruyne, E. Falco, A. Ferrero, M. Z. Muallem, J. Kerger, E. Garcia-Martinez, S. Pignata, J. Sehouli, T. Van Gorp, C. Gennigens, M. J. Rubio

Summary: This study aimed to establish the role of nintedanib in first-line recurrent/metastatic cervical cancer. The results showed that nintedanib improved the progression-free survival compared to the carboplatin-paclitaxel group. The nintedanib group had a longer median overall survival and a higher RECIST response rate.

GYNECOLOGIC ONCOLOGY (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee

Lori M. Strachowski, Priyanka Jha, Catherine H. Phillips, Misty M. Blanchette Porter, Wouter Froyman, Phyllis Glanc, Yang Guo, Maitray D. Patel, Caroline Reinhold, Elizabeth J. Suh-Burgmann, Dirk Timmerman, Rochelle F. Andreotti

Summary: The Ovarian-Adnexal Reporting and Data System (O-RADS) US is a standardized scoring system for ovarian and adnexal lesions, providing risk stratification and management guidance. The latest update includes additional morphologic features and emphasizes the use of MRI for further evaluation.

RADIOLOGY (2023)

Letter Computer Science, Artificial Intelligence

The TRIPOD-P reporting guideline for improving the integrity and transparency of predictive analytics in healthcare through study protocols

Paula Dhiman, Rebecca Whittle, Ben Van Calster, Marzyeh Ghassemi, Xiaoxuan Liu, Melissa D. McCradden, Karel G. M. Moons, Richard D. Riley, Gary S. Collins

NATURE MACHINE INTELLIGENCE (2023)

Meeting Abstract Oncology

Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Susana N. Banerjee, Sandro Pignata, Nicoletta Colombo, John William Moroney, Casey Cosgrove, Jung-Yun Lee, Andrzej Roszak, Shani Breuer, Jacqueline Maria Tromp, Diana Bello-Roufai, Lucy Gilbert, Rowan Miller, Tashanna K. N. Myers, Yuemei Wang, Anna Berkenblit, Domenica Lorusso, Toon Van Gorp

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Health Care Sciences & Services

Multiclass risk models for ovarian malignancy: an illustration of prediction uncertainty due to the choice of algorithm

Ashleigh Ledger, Jolien Ceusters, Lil Valentin, Antonia Testa, Caroline Van Holsbeke, Dorella Franchi, Tom Bourne, Wouter Froyman, Dirk Timmerman, Ben Van Calster

Summary: Assessing the malignancy risk of ovarian tumors is crucial for selecting appropriate management. In this study, six algorithms were compared to estimate the probabilities of different types of ovarian tumors. The models developed showed good performance, but individual probability estimates varied substantially.

BMC MEDICAL RESEARCH METHODOLOGY (2023)

Article Obstetrics & Gynecology

Effects of chemotherapy on ovaries of pregnant mice

Teska Schuurman, Ji-Ying Song, Vera Wolters, Marieke van de Ven, Nienke van Trommel, Ina Beerendonk, Frederic Amant, Christianne Lok

Summary: This study found that chemotherapy can cause damage to the maternal ovaries during pregnancy, and the extent of this damage depends on the type of chemotherapy and the duration of exposure. Short-term exposure leads to more severe damage, but it might be temporary. Chemotherapy also results in the loss of primordial follicles and DNA damage, with paclitaxel causing the least damage.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

No Data Available